PI Industries FY26 Net Profit at ₹14,348 Million

PI Industries has announced its audited standalone and consolidated financial results for the year ended March 31, 2026. The company reported a total income of ₹64,904 million for the financial year, with a net profit of ₹14,348 million.

Financial Performance

The standalone financial results for the year ended March 31, 2026, show a profit for the period of ₹14,348 million. Revenue from operations stood at ₹61,827 million, while other income contributed ₹3,077 million. Total expenses for the year were recorded at ₹45,592 million. For the quarter ended March 31, 2026, revenue from operations was ₹13,914 million and net profit was ₹1,978 million.

Parameter	Amount (₹ Million)
Revenue from Operations	61,827
Other Income	3,077
Total Income	64,904
Total Expenses	45,592
Net Profit for the Year	14,348

Dividend Declaration

The Board of Directors, at their meeting held on May 19, 2026, recommended a final dividend of ₹10 per equity share. This is in addition to the interim dividend of ₹5 per equity share paid during the year, bringing the total dividend for the year to ₹15 per share. The dividend is subject to the approval of shareholders at the ensuing Annual General Meeting.

Operational Highlights

The company’s earnings per share (EPS) for the year stood at ₹94.57 on a basic basis and ₹94.56 on a diluted basis. The paid-up equity share capital remained at ₹152 million. The financial results were reviewed by the Audit Committee and approved by the Board.

Board and Key Appointments

During the meeting held on May 19, 2026, the Board approved the re-appointment of M/s K.G. Goyal & Co. as Cost Auditors for the financial year 2026-27. Mr. Rajnish Sarna resigned from the office of Joint Managing Director effective May 19, 2026, to focus on health recovery, and will continue as a Non-Executive, Non-Independent Director. The Board appointed Dr. Atul Kumar Gupta as an Additional Director and Whole Time Director for a period of three years commencing May 19, 2026, subject to shareholder approval. Additionally, Dr. Marco Busch was designated as Senior Management Personnel.

1 Day	5 Days	1 Month	6 Months	1 Year	5 Years
-7.15%	-3.22%	-7.60%	-15.66%	-22.82%	+12.83%

PI Industries announced its financial results for the quarter and year ended March 31, 2026. The company reported a decline in profitability for FY26, impacted by a volatile global situation and customer delivery schedules. The Board has approved a final dividend of INR 10 per share for FY25-26, taking the total dividend for the fiscal year to INR 15 per share.

Q4 FY26 Financial Performance

The company faced a challenging operating environment during the quarter, leading to a contraction in key financial metrics. Revenue from operations decreased by 12% year-on-year to INR 15,652 Mn. This decline was driven by a 15% drop in Agchem Exports due to an industry contraction and a ~9% softening in Domestic revenue, although Pharma revenue grew by 23%.

Metric (INR Mn)	Q4 FY26	Q4 FY25	% YoY
Revenue	15,652	17,871	(12)%
EBITDA	3,373	4,569	(26)%
Net Profit	2,002	3,305	(39)%
EBITDA Margin %	21.55%	25.60%	(405) bps

Despite the revenue decline, the Gross Margin improved by 277 basis points to 58%, driven by a favorable product mix and cost discipline. However, the EBITDA margin contracted to 21.55% from 25.60% in the prior year. Net Profit for the quarter stood at INR 2,002 Mn.

Annual Performance FY26

For the full fiscal year FY26, PI Industries reported a revenue of INR 67,137 Mn, a decrease of 16% from the previous year. EBITDA for the year was INR 17,053 Mn, down 22% YoY, while Net Profit stood at INR 13,208 Mn, a decrease of 20%. The company maintained a resilient EBITDA margin of 25% for the year.

The Net Profit for FY26 included exceptional income from the writeback of contingent consideration amounting to INR 1,260 Mn, partially offset by additional provisioning of INR 229 Mn as per the New labor code. The company generated a Cash Flow from Operating Activities of INR 4,740 Mn in FY26.

Strategic Updates and Outlook

PI Industries continued to invest in growth, with total capital expenditure for FY26 reaching INR 11,508 Mn. The company commercialized 5 new molecules in Exports and 4 products in the Domestic Agri Brands segment. In the Pharma business, revenue grew by 40% YoY to INR 3,005 Mn, driven by new customer onboarding.

Looking ahead, the company remains positive for growth in FY27, supported by a strong order book and plans to launch 5+ new molecules. The balance sheet remains robust with surplus cash net of debt at INR 34,265 Mn, providing strategic flexibility to navigate the cycle and pursue future investments.